Jump to content

Michel Meunier

From Wikipedia, the free encyclopedia
Michel Meunier (physicist)
NationalityCanadian
Alma materPolytechnique Montréal, Massachusetts Institute of Technology
Scientific career
FieldsEngineering Physics and Biomedical Engineering
InstitutionsPolytechnique Montréal
Websitelp2l.polymtl.ca

Michel Meunier is a professor of engineering physics and biomedical engineering at Polytechnique Montréal, a position has he held since 1986. He was recently the acting director of the Department of Engineering Physics from 2019 to 2020. He is the director of the Laser Processing and Plasmonics Laboratory (LP2L), which he founded in 1988, whose mission is to develop diagnostic and therapeutic technologies based on plasmonics and the optical properties of colloidal nanoparticles.

University education

[edit]

Michel Meunier received his B.Eng. and M.A.Sc. in engineering physics from Polytechnique Montréal in 1978 and 1980, respectively, and his doctorate from the Massachusetts Institute of Technology in 1984.[1]

Career

[edit]

Michel Meunier has been a professor of Engineering Physics at Polytechnique Montréal since 1986 and was the interim director of the Department of Engineering Physics for the years 2019/2020.[1]

Research

[edit]

Holder of a Canada Research Chair from 2002 to 2016, Prof. Michel Meunier is recognized for his research in the field of nanotechnology and laser-matter interaction for medical applications. He is notably one of the developers of optoporation, which consists of carrying out cell gene transfection using an ultra-fast pulsed laser (femtosecond laser) and of plasmonic nanoparticles, typically gold or gold-silver alloy.[2][3]

The activities of his laboratory, the LP2L, mainly focuses on four research axes:

  • Femtosecond engineering
  • Biomedical nanophotonics
  • Plasmonic nanobiomarker imaging
  • Laser nanosurgery

Entrepreneurship

[edit]
  • Michel Meunier is one of the cofounders of the company LTRIM Technologies, Inc., founded in 1998.[4] Notably, LTRIM Technologies has commercialized a new laser trimming technique for analog circuits.
  • Michel Meunier is a joint holder of a patent granted in 2015 for the chemical synthesis of spherical gold-silver alloy nanoparticles used as biomarkers.[4]
  • He is also one of the cofounders of the start-up VEGA BioImaging in 2021, which specializes in the detection and characterization of plasmonic nanoparticles in solution or in a cellular environment.[5]

Prizes and distinctions

[edit]

References

[edit]
  1. ^ a b "Directory of Experts: Meunier, Michel". Polytechnique Montréal. 10 October 2017. Retrieved 2022-08-02.
  2. ^ "Michel Meunier plenary talk: A New Plasmonics Enhanced Ultrafast Laser". spie.org. Retrieved 2020-08-17.
  3. ^ "A major step toward non-viral ocular gene therapy using laser and nanotechnology". EurekAlert!. Retrieved 2020-08-17.
  4. ^ a b "TECHNOLOGIES LTRIM INC". www.quebecentreprises.com. Retrieved 2020-08-17.
  5. ^ "About Us - VEGA BioImaging". vegabioimaging.com. 23 January 2020. Retrieved 2022-08-02.
  6. ^ "Michel Meunier - Prix Synergie pour l'innovation - Conseil de recherches en sciences naturelles et en génie du Canada (CRSNG)". Prix et distinctions (in French). 2012-01-27. Retrieved 2020-08-17.
  7. ^ "Directory of Fellows: Meunier, Michel". The Canadian Academy of Engineering. Retrieved 2022-08-02.
  8. ^ "Michel Meunier". spie.org. Retrieved 2020-08-17.
  9. ^ "2012 Fellows - OSA". osa.org. January 2012. Retrieved 17 August 2020.
  10. ^ Éducation et Enseignement supérieur Québec (24 May 2016). "Remise prix Guy Rocher". youtube.com. Retrieved 19 August 2020.